Inflammation in rosacea and acne: Implications for patient care

Journal of Drugs in Dermatology

Volumn 10, Issue 6, 2011, Pages 614-620

  Fleischer Jr , Alan B ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZELAIC ACID; BENZOYL PEROXIDE; CATHELICIDIN; COLECALCIFEROL; DAPSONE; DICARBOXYLIC ACID; DOXYCYCLINE; INTERLEUKIN 10; INTERLEUKIN 8; ISOTRETINOIN; KALLIKREIN 5; METRONIDAZOLE; MINOCYCLINE; ORAL CONTRACEPTIVE AGENT; PSORIASIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RETINOID; SULFACETAMIDE PLUS SULFUR; TETRACYCLINE; TUMOR NECROSIS FACTOR;

ACNE; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; INNATE IMMUNITY; LOW DRUG DOSE; PAPULE; PATHOGENESIS; PATIENT CARE; PUSTULE; REVIEW; ROSACEA; SIGNAL TRANSDUCTION; SKIN INFLAMMATION; VITAMIN D RESPONSIVE ELEMENT;

ACNE VULGARIS; ANTI-INFLAMMATORY AGENTS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; ROSACEA;

EID: 80053071554     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Bevins CL, Liu FT. Rosacea: Skin innate immunity gone awry? Nat Med. 2007;13(8):904-906. (Pubitemid 47222032)
2. Kurokawa I, Danby FW, Ju Q, et al. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol. 2009;18(10):821-832.
3. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51(3):327-341. Quiz 342-344.
4. Draelos ZD. Facial hygiene and comprehensive management of rosacea. Cutis. 2004;73(3):183-187. (Pubitemid 38453136)
5. Forton F, Germaux MA, Brasseur T, et al. Demodicosis and rosacea: Epidemiology and significance in daily dermatologic practice. J Am Acad Dermatol. 2005;52(1):74-87. (Pubitemid 40038938)
6. Lacey N, Delaney S, Kavanagh K, Powell FC. Mite-related bacterial antigens stimulate inflammatory cells in rosacea. Br J Dermatol. 2007;157(3):474-481. (Pubitemid 47256121)
7. Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13(8):975-980. (Pubitemid 47222043)
8. Yamasaki K, Gallo RL. The molecular pathology of rosacea. J Dermatol Sci. 2009;55(2):77-81.
9. Voegeli R, Rawlings AV, Doppler S, Schreier T. Increased basal transepidermal water loss leads to elevation of some but not all stratum corneum serine proteases. Int J Cosmet Sci. 2008;30(6):435-442.
10. Aroni K, Tsagroni E, Kavantzas N, Patsouris E, Ioannidis E. A study of the pathogenesis of rosacea: How angiogenesis and mast cells may participate in a complex multifactorial process. Arch Dermatol Res. 2008;300(3):125-131.
11. Wang TT, Nestel FP, Bourdeau V, et al. Cutting edge: 1,25- dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol. 2004;173(5):2909-2912. (Pubitemid 39141992)
12. Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J. 2005;19(9):1067-1077. (Pubitemid 40946432)
13. Weber G, Heilborn JD, Chamorro Jimenez CI, Hammarsjo A, Torma H, Stahle M. Vitamin D induces the antimicrobial protein hCAP18 in human skin. J Invest Dermatol. 2005;124(5):1080-1082. (Pubitemid 40629115)
14. Schauber J, Gallo RL. Antimicrobial peptides and the skin immune defense system. J Allergy Clin Immunol. 2008;122(2):261-266.
15. Schauber J, Gallo RL. The vitamin D pathway: A new target for control of the skin's immune response? Exp Dermatol. 2008;17(8):633-639. (Pubitemid 352044354)
16. Engel A, Johnson ML, Haynes SG. Health effects of sunlight exposure in the United States. Results from the first National Health and Nutrition Examination Survey, 1971-1974. Arch Dermatol. 1988;124(1):72-79. (Pubitemid 18027138)
17. Zheng Y, Niyonsaba F, Ushio H, et al. Cathelicidin LL-37 induces the generation of reactive oxygen species and release of human alpha-defensins from neutrophils. Br J Dermatol. 2007;157(6):1124-1131. (Pubitemid 350115677)
18. Jones DA. Rosacea, reactive oxygen species, and azelaic acid. J Clin Aesthetic Derm. 2009;1(1):5.
19. Caillon F, O'Connell M, Eady EA, et al. Interleukin-10 secretion from CD14+ peripheral blood mononuclear cells is downregulated in patients with acne vulgaris. Br J Dermatol. 20 2009.
20. Bialecka A, Mak M, Biedron R, Bobek M, Kasprowicz A, Marcinkiewicz J. Different pro-inflammatory and immunogenic potentials of Propionibacterium acnes and Staphylococcus epidermidis: Implications for chronic inflammatory acne. Arch Immunol Ther Exp (Warsz). 2005;53(1):79-85. (Pubitemid 40364728)
21. Vowels BR, Yang S, Leyden JJ. Induction of proinflammatory cytokines by a soluble factor of Propionibacterium acnes: Implications for chronic inflammatory acne. Infect Immun. 1995;63(8):3158-3165.
22. Jeremy AH, Holland DB, Roberts SG, Thomson KF, Cunliffe WJ. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol. 2003;121(1):20-27. (Pubitemid 36900450)
23. Lee DY, Yamasaki K, Rudsil J, et al. Sebocytes express functional cathelicidin antimicrobial peptides and can act to kill propionibacterium acnes. J Invest Dermatol. 2008;128(7):1863-1866. (Pubitemid 351847367)
24. Holland DB, Jeremy AH, Roberts SG, Seukeran DC, Layton AM, Cunliffe WJ. Inflammation in acne scarring: A comparison of the responses in lesions from patients prone and not prone to scar. Br J Dermatol. 2004;150(1):72-81. (Pubitemid 38234009)
25. Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: An update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009;60(suppl 5):1S-50S.
26. Passi S. Pharmacology and pharmacokinetics of azelaic acids. Rev Contemp Pharmacother. 1993;4:7.
27. Draelos Z, Kayne AL. Implications of azelaic acid's multiple mechanisms of action: Therapeutic versatility. American Academy of Dermatology 66th Annual Meeting. Vol San Antonio, TX; 2008.
28. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: Results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48(6):836-845. (Pubitemid 36706214)
29. Elewski BE, Fleischer AB, Jr., Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: Results of a randomized trial. Arch Dermatol. 2003;139(11):1444-1450. (Pubitemid 37433134)
30. AARS. Rosacea Medical Management Guidelines. Fall Clinical Dermatology Conference. Vol Las Vegas, NV; 2007.
31. Yamasaki K, Gallo RL. Azelaic Acid (AcA) Gel 15% Decreases Kallikrein 5 in Epidermal Keratinocytes: Critical Elements in Production of Cathelicidin and the Pathogenesis of Rosacea. Fall Clinical Dermatology Conference. Vol Las Vegas, NV; 2009b.
32. Weinberg JM. The anti-inflammatory effects of tetracyclines. Cutis. 2005;75(suppl 4):6-11. (Pubitemid 40627619)
33. Webster G, Del Rosso JQ. Anti-inflammatory activity of tetracyclines. Dermatol Clin. 2007;25(2):133-135, v. (Pubitemid 46566395)
34. Korting HC, Schollmann C. Tetracycline actions relevant to rosacea treatment. Skin Pharmacol Physiol. 2009;22(6):287-294.
35. Wolf JE, Jr., Kerrouche N, Arsonnaud S. Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. Cutis. 2006;77(suppl 4):3-11. (Pubitemid 43723532)
36. McClellan KJ, Noble S. Topical metronidazole. A review of its use in rosacea. Am J Clin Dermatol. 2000;1(3):191-199.
37. Gupta AK, Nicol K. The use of sulfur in dermatology. J Drugs Dermatol. 2004;3(4):427-431.
38. Del Rosso JQ. Evaluating the role of topical therapies in the management of rosacea: Focus on combination sodium sulfacetamide and sulfure formulations. Cutis. 2004;73(suppl 1):5.
39. Baldwin HE. Oral therapy for rosacea. J Drugs Dermatol. 2006;5(1):16-21.
40. Sapadin AN, Fleischmajer R. Tetracyclines: Nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54(2):258-265. (Pubitemid 43144395)
41. Wise RD. Submicrobial doxycycline and rosacea. Compr Ther. 2007;33(2):78-81. (Pubitemid 350242504)
42. Bikowski JB. Subantimicrobial dose doxycycline for acne and rosacea. Skinmed. 2003;2(4):234-245.
43. Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56(5):791-802. (Pubitemid 46561002)
44. Fowler JF, Jr. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol. 2007;6(6):641-645.
45. Del Rosso JQ. Efficacy of Topical Azelaic Acid (AzA) Gel 15% Plus Oral Doxycycline 40 mg vs. Metronidazole Gel 1% Plus Oral Doxycycline 40 mg in Mild-to-Moderate Papulopustular Rosacea. J Drugs Dermatol. 2010; In Press.
46. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: A report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(suppl 1):1S-37S.
47. Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: A status report. Dermatol Clin. 2009;27(1):1-15.
48. Thiboutot DM, Gollnick HP. Treatment considerations for inflammatory acne: Clinical evidence for adapalene 0.1% in combination therapies. J Drugs Dermatol. 2006;5(8):785-794.
49. Bikowski JB. Mechanisms of the comedolytic and anti-inflammatory properties of topical retinoids. J Drugs Dermatol. 2005;4(1):41-47.
50. Thielitz A, Gollnick H. Topical retinoids in acne vulgaris: Update on efficacy and safety. Am J Clin Dermatol. 2008;9(6):369-381.
51. Sagransky M, Yentzer BA, Feldman SR. Benzoyl peroxide: A review of its current use in the treatment of acne vulgaris. Expert Opin Pharmacother. 2009;10(15):2555-2562.
52. Tanghetti EA, Popp KF. A current review of topical benzoyl peroxide: New perspectives on formulation and utilization. Dermatol Clin. 2009;27(1):17-24.
53. Smith SR, Kempers S. A Study of 5.5% Benzoyl Peroxide Microsphere Cream Versus 6% Benzoyl Peroxide Gel in the Treatment of Acne Vulgaris. Cosmetic Dermatology. 2006;19(8):6.
54. Scheinfeld N. Aczone, a topical gel formulation of the antibacterial, anti-inflammatory dapsone for the treatment of acne. Curr Opin Investig Drugs. 2009;10(5):474-481.
55. Bender A, Zapolanski T, Watkins S, et al. Tetracycline suppresses ATP gamma S-induced CXCL8 and CXCL1 production by the human dermal microvascular endothelial cell-1 (HMEC-1) cell line and primary human dermal microvascular endothelial cells. Exp Dermatol. 2008;17(9):752-760.
56. Simonart T, Dramaix M, De Maertelaer V. Efficacy of tetracyclines in the treatment of acne vulgaris: A review. Br J Dermatol. 2008;158(2):208-216.
57. Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007;56(4):651-663. (Pubitemid 46400177)
58. Kurokawa J. [Nongenomic actions via sex hormone receptors]. Nippon Yakurigaku Zasshi. 2009;134(2):105-106.
59. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2009(3):CD004425.
60. Maloney JM, Dietze P Jr, Watson D, et al. A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 microg ethinylestradiol in the treatment of acne vulgaris: Lesion counts, investigator ratings and subject self-assessment. J Drugs Dermatol. 2009;8(9):837-844.
61. Lucky AW, Koltun W, Thiboutot D, et al. A combined oral contraceptive containing 3-mg drospirenone/ 20-microg ethinyl estradiol in the treatment of acne vulgaris: A randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment. Cutis. 2008;82(2):143-150.
62. Koltun W, Lucky AW, Thiboutot D, et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: A randomized, double-blind, placebo-controlled trial. Contraception. 2008;77(4):249-256.
63. Maloney JM, Dietze P Jr, Watson D, et al. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: A randomized controlled trial. Obstet Gynecol. 2008;112(4):773-781.